Lilly director receives deferred stock award

Fyrwald J Erik reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Fyrwald J Erik reported acquisition or exercise transactions in this Form 4 filing.

ELI LILLY & Co director J Erik Fyrwald received a grant of 8.7809 shares of common stock equivalent on a deferred basis. The award was priced at $1,129.35 per share and was taken in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan. After this grant, Fyrwald holds a total of 75,401.0968 shares of Lilly common stock directly, including these deferred stock units, which will be settled in shares after his separation from service.

Insider Trade Summary

Grant/Award: 8.7809 shares

Grant/Award 1 txn

Insider Fyrwald J Erik

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8.7809	$1,129.35	$10K

Holdings After Transaction: Common Stock — 75,401.0968 shares (Direct)

Footnotes (1)

1. F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Key Figures

Shares granted: 8.7809 shares Grant price: $1,129.35 per share Total holdings after grant: 75,401.0968 shares +1 more

4 metrics

Shares granted 8.7809 shares Deferred stock units granted to director on 2026-06-15

Grant price $1,129.35 per share Valuation used for the 8.7809-share award

Total holdings after grant 75,401.0968 shares Director’s direct Lilly common stock holdings after transaction

Transaction code A (grant, award, or other acquisition) Indicates compensation-related acquisition, not open-market trade

Key Terms

Lilly Directors' Deferral Plan, deferred in lieu of cash compensation, stock units, grant, award, or other acquisition

4 terms

Lilly Directors' Deferral Plan financial

"as stock units under the Lilly Directors' Deferral Plan and will be settled"

deferred in lieu of cash compensation financial

"the shares acquired pursuant to this filing have been deferred in lieu of cash compensation"

stock units financial

"deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan"

Stock units are individual pieces of ownership in a company, like slices of a pie that together make up the whole business. They matter to investors because each unit represents a claim on the company’s assets, profits and sometimes voting power, and changes in the number or value of these units affect ownership percentages, potential dividends and share dilution — all of which influence an investment’s worth.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ELI LILLY (LLY) director J Erik Fyrwald report in this Form 4?

Director J Erik Fyrwald reported an acquisition of 8.7809 Lilly common stock equivalents. These were granted as deferred stock units instead of cash compensation and will later settle in actual shares after his separation from service from ELI LILLY & Co.

How many ELI LILLY (LLY) shares does J Erik Fyrwald hold after this transaction?

After this award, J Erik Fyrwald directly holds 75,401.0968 shares of ELI LILLY common stock. This total includes the 8.7809 shares’ worth of stock units granted in this filing, which will be settled in shares following his separation from service.

What type of transaction is reported for ELI LILLY (LLY) director J Erik Fyrwald?

The transaction is a grant or award acquisition coded “A” on Form 4. It reflects compensation taken as 8.7809 deferred stock units instead of cash, rather than an open‑market purchase or sale of ELI LILLY common stock by the director.

At what price was J Erik Fyrwald’s ELI LILLY (LLY) stock award valued?

The 8.7809 share equivalent stock award to J Erik Fyrwald was valued at $1,129.35 per share. This price is used solely for the compensation calculation and reporting and does not necessarily represent a trade executed in the open market.

How are J Erik Fyrwald’s deferred stock units in ELI LILLY (LLY) settled?

According to the filing, the stock units were issued under the Lilly Directors' Deferral Plan. They are deferred in lieu of cash compensation and will be settled in actual shares of ELI LILLY common stock after J Erik Fyrwald separates from service as a director.

Is this ELI LILLY (LLY) Form 4 a market buy or sell by J Erik Fyrwald?

No. The Form 4 shows a compensation-related grant coded “A,” not a market buy or sell. J Erik Fyrwald received 8.7809 share equivalents as deferred stock units instead of cash, to be settled in ELI LILLY common stock at a later time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fyrwald J Erik

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS INDIANA 46285

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		A		8.7809(1)	A	$1,129.35	75,401.0968	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Remarks:

	/s/ Jonathan Groff for J. Erik Fyrwald, pursuant to authorization on file	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)